论文部分内容阅读
目的观察复方斑蝥胶囊治疗TE方案乳腺癌新辅助化疗的临床疗效。方法 68例住院患者随机分为治疗组(34例)和对照组(34例)。治疗组在新辅助化疗治疗的同时,加用复方斑蝥胶囊辅助治疗。结果两组患者全血分析各项指标变化比较,差异有显著性(P<0.05),在化疗第1,2周期后,治疗组的外周血T细胞亚群等检测值均较治疗前明显增高(P<0.05)。结论复方斑蝥胶囊协同乳腺癌新辅助化疗,能减轻毒性反应,按计划实行手术,提高患者免疫力,疗效确切,值得推广。
Objective To observe the clinical efficacy of compound cantharidin capsule in the treatment of TE regimen neoadjuvant chemotherapy. Methods Sixty-eight inpatients were randomly divided into treatment group (34 cases) and control group (34 cases). Treatment group in the neoadjuvant chemotherapy, plus compound cantharidin capsule adjuvant therapy. Results The changes of the indexes in the whole blood of the two groups were significantly different (P <0.05). After the first and second cycles of chemotherapy, the T cell subsets in the peripheral blood in the treatment group were significantly higher than those before treatment (P <0.05). Conclusion Compound cantharidin capsule in combination with neoadjuvant chemotherapy for breast cancer can reduce the toxic reaction, implement surgery according to plan, and improve patient immunity. The curative effect is worthy of promotion.